Orphan Drug Designation granted to CK0803 for Amyotrophic Lateral Sclerosis CK0803 is CNS Homing Tregs expressing CXCR3hi, ...
The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to treat ALS.
Medicare beneficiaries with amyotrophic lateral sclerosis (ALS) were found to have more than 3 times the Medicare expenditures and beneficiary liability of the average Medicare beneficiary.
Many long-COVID symptoms in people older than 65 years mimic signs of early aging, particularly cognitive, cardiac, and kidney issues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback